Market Newsdesk

Materion Corporation to Hold Annual Shareholder’s Meeting May 17

MAYFIELD HEIGHTS, Ohio–(BUSINESS WIRE)–
Materion Corporation (NYSE: MTRN) will hold its annual shareholder’s meeting (the Annual Meeting) at the Boston Marriott Newton hotel in Newton, Massachusetts on May 17, 2023, at 8:00 a.m. (EDT).

About Materion

Materion Corporation is a global leader in advanced materials solutions for high-performance industries including semiconductor, industrial, aerospace & defense, energy and automotive. With nearly 100 years of expertise in specialty engineered alloy systems, inorganic chemicals and powders, precious and non-precious metals, beryllium and beryllium composites, and precision filters and optical coatings, Materion partners with customers to enable breakthrough solutions that move the world forward. Headquartered in Mayfield Heights, Ohio, the company employs more than 3,700 talented people worldwide, serving customers in more than 60 countries.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230302005758/en/

Investors:

Kyle Kelleher

(216) 383-4931

[email protected]

Media:

Jason Saragian

(216) 383-6893

[email protected]

KEYWORDS: United States North America Massachusetts Ohio

INDUSTRY KEYWORDS: Machinery Machine Tools, Metalworking & Metallurgy Mining/Minerals Technology Natural Resources Other Manufacturing Semiconductor Steel Engineering Chemicals/Plastics Automotive Manufacturing Aerospace Manufacturing

MEDIA:

Posted on March 2, 2023 5:27 pm

Global Indemnity Group, LLC Announces Quarterly Distribution

Global Indemnity Group, LLC Announces Quarterly Distribution

WILMINGTON, Del.–(BUSINESS WIRE)–
Global Indemnity Group, LLC (NYSE:GBLI) (“GBLI”) announced today its Board of Directors has approved a distribution payment of $0.25 per common share to be paid on March 31, 2023 to all shareholders of record as of the close of business on March 24, 2023.

About Global Indemnity Group, LLC and its subsidiaries

Global Indemnity Group, LLC (NYSE:GBLI), through its several direct and indirect wholly owned subsidiary insurance companies, provides both admitted and non-admitted specialty property and casualty insurance coverages and individual policyholder coverages in the United States through its United National/Penn-America Binding & Programs Unit and its InsurTech Unit, as well as reinsurance worldwide.

For more information, visit the Company’s website at www.gbli.com.

Forward-Looking Information

The forward-looking statements contained in this press release do not address a number of risks and uncertainties. Investors are cautioned that Global Indemnity’s actual results may be materially different from the estimates expressed in, or implied, or projected by, the forward-looking statements. These statements are based on estimates and information available to us at the time of this press release. All forward-looking statements in this press release are based on information available to Global Indemnity as of the date hereof. Please see Global Indemnity’s filings with the Securities and Exchange Commission for a discussion of risks and uncertainties which could impact the company and for a more detailed explication regarding forward-looking statements. Global Indemnity does not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made.

[1] Disseminated pursuant to the “safe harbor” provisions of Section 21E of the Security Exchange Act of 1934.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230302005041/en/

Media

Stephen W. Ries

Head of Investor Relations

(610) 668-3270

[email protected]

KEYWORDS: Delaware United States North America

INDUSTRY KEYWORDS: Insurance Professional Services

MEDIA:

Logo

Alexion advances commitment to transform patient outcomes in rare neurological diseases at AAN 2023

New insights from industry-leading portfolio will demonstrate the impact of C5 inhibition in treating patients with gMG and NMOSD

Data will showcase breadth and potential of early to late stage rare disease pipeline

WILMINGTON, Del.–(BUSINESS WIRE)–
Alexion, AstraZeneca Rare Disease, will showcase the potential for its pioneering therapies to redefine the treatment landscape for certain rare neurological diseases at the American Academy of Neurology (AAN) Annual Meeting, April 22-27, 2023. The company will present 19 abstracts, including eight oral presentations, across generalized myasthenia gravis (gMG), neuromyelitis optica spectrum disorder (NMOSD), Wilson disease and dermatomyositis.

Presentations of clinical and real-world evidence will offer new insights about the efficacy and safety of ULTOMIRIS^® (ravulizumab-cwvz) and SOLIRIS^® (eculizumab) and the crucial role C5 inhibition can play in improving outcomes for patients with the most common forms of gMG and NMOSD. New Phase I data for gefurulimab (ALXN1720), an investigational, self-administered, third generation C5 complement inhibitor, will further support ongoing Phase III clinical development in gMG, representing continued innovation for the rare disease community.

Marc Dunoyer, Chief Executive Officer, Alexion, said: “Our presentations at AAN reinforce the depth and strength of our expanding rare neurology portfolio and demonstrate the potential for our C5 inhibitors to transform care for people living with gMG and NMOSD. We continue to deliver on our commitment to understand patient experiences and innovate to meet the needs of the rare disease communities we serve.”

Delivering on the promise of C5 inhibition in rare neurology

Presentations will expand on results from the CHAMPION-MG Phase III trial, which supported the US approval of ULTOMIRIS, the first and only long-acting C5 complement inhibitor, for adults with anti-acetylcholine receptor (AChR) antibody-positive (Ab+) gMG. This includes an exploratory analysis showing patients who received ULTOMIRIS were more likely to see improvements in overall disease status as compared to placebo.

Additionally, findings from a US-based disease registry will provide real-world evidence for first-in-class C5 inhibitor SOLIRIS, demonstrating treatment response for the majority of gMG patients in a broad representative population. Further, poster presentations will be showcased for gefurulimab (ALXN1720), an investigational C5 inhibitor optimized for subcutaneous administration, including trial design and methodology for the ongoing PREVAIL Phase III trial in adults with AChR Ab+ gMG.

New data on pharmacodynamics and pharmacokinetics and updated analyses from the CHAMPION-NMOSD Phase III trial will reinforce the critical benefits of C5 inhibition in anti-aquaporin-4 (AQP4) Ab+ NMOSD treatment and the potential of ULTOMIRIS to substantially reduce the risk of relapse in a broad range of patients.

Improving awareness of patient experiences

A poster presentation will share insights from interviews with NMOSD patients to help illustrate the debilitating effects of NMOSD on mobility and activities of daily living. These findings will contribute to a more robust and authentic understanding of the lasting impact of this disease, underscoring the importance of timely treatment in NMOSD to prevent relapses that can result in cumulative disability.

Alexion presentations during AAN 2023

Lead author	Abstract title	Presentation details
gMG
Bril, Vera	Ravulizumab in adults with generalized myasthenia gravis: A sub-analysis of the Phase 3 CHAMPION MG study, according to chronic IVIg use at study entry	Poster Presentation P1.5-013 April 23, 2023 8:00 – 9:00 AM ET
Muppidi, Srikanth	Achievement of improved post-intervention status in patients with generalized myasthenia gravis treated with ravulizumab during the CHAMPION MG study	Oral Presentation S5.008 April 23, 2023 2:24 PM ET
Habib, Ali	Ravulizumab for the treatment of generalized myasthenia gravis: timing of response	Poster Presentation P1.5-004 April 23, 2023 8:00 – 9:00 AM ET
Basoff, Daniel	Comorbidities in patients with myasthenia gravis in the USA: a retrospective claims database analysis	Poster Presentation P1.5-003 April 23, 2023 8:00 – 9:00 AM ET
Rodrigues, Ema	Incidence and prevalence of myasthenia gravis in the United States: a claims-based analysis	Oral Presentation S19.007 April 24, 2023 4:42 PM ET
Greene, Ericka	Myasthenia gravis activities of daily living (MG-ADL) response to eculizumab treatment in patients from the Generalized Myasthenia Gravis Registry	Poster Presentation P1.5-020 April 23, 2023 8:00 – 9:00 AM ET
Pulley, Michael	Change in concomitant therapies for generalized myasthenia gravis in patients receiving eculizumab: a retrospective analysis of registry data	Poster Presentation P1.5-002 April 23, 2023 8:00 – 9:00 AM ET
Brandsema, John	A Phase 3, open-label, multicenter study to evaluate eculizumab in adolescents with refractory generalized myasthenia gravis	Oral Presentation S5.009 April 23, 2023 2:36 PM ET
Ortiz, Stephan	Safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of subcutaneous and intravenous ALXN1720 in healthy volunteers: a Phase 1, randomized, double-blind, placebo-controlled, single and multiple ascending dose study	Poster Presentation P1.5-016 April 23, 2023 8:00 – 9:00 AM ET
Howard, James	Study design and methodology of the PREVAIL trial: a Phase 3, randomized, double-blind, placebo-controlled study of the safety and efficacy of subcutaneous ALXN1720 in adults with generalized myasthenia gravis	Poster Presentation P1.5-008 April 23, 2023 8:00 – 9:00 AM ET
Laforêt, Pascal	Identifying digital biomarkers for the self-monitoring of patients living with generalized myasthenia gravis: a proof of concept*	Poster Presentation P7.8-007 April 25, 2023 8:00 – 9:00 AM ET
NMOSD
Ortiz, Stephan	Pharmacokinetics and pharmacodynamics of ravulizumab in adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder during the Phase 3 CHAMPION-NMOSD trial	Oral Presentation S5.004 April 23, 2023 1:36 PM ET
Pittock, Sean	Efficacy and safety of ravulizumab in adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: outcomes from the Phase 3 CHAMPION-NMOSD trial	Oral Presentation S5.002 April 23, 2023 1:12 PM ET
Levy, Michael	Efficacy subgroup analyses from the Phase 3 CHAMPION-NMOSD trial in adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder	Oral Presentation S5.003 April 23, 2023 1:24 PM ET
Bernitsas, Evanthia	Characterizing the impact of NMOSD on mobility, daily activities, and social activities through patient interviews	Poster Presentation P13.5-011 April 27, 2023 8:00 – 9:00 AM ET
Levy, Michael	NMOSDCopilot: feasibility of smartphone-based digital biomarkers for the self-assessment of vision, motor and cognitive functions in neuromyelitis optica spectrum disorder*	Oral Presentation S50.002 April 27, 2023 3:42 PM ET
Wilson disease
Bega, Danny	Efficacy and safety of ALXN1840 versus standard of care in Wilson disease: primary results from an ongoing Phase 3, randomized, controlled, rater-blinded trial	Clinical Trials Plenary Session April 25, 2023 9:15 – 11:30 AM ET
Hedera, Peter	Neurological manifestations of Wilson disease in treatment-naive patients and in patients receiving standard of care	Poster Presentation P11.4-005 April 26, 2023 11:45 AM – 12:45 PM ET
Dermatomyositis
Kielhorn, Adrian	Treatment utilization in dermatomyositis: an analysis of electronic medical records in the United States	Poster Presentation P9.5-032 April 25, 2023 5:30 – 6:30 PM ET

*Ad Scientiam research study supported by Alexion

INDICATION(S) & IMPORTANT SAFETY INFORMATION for ULTOMIRIS^® (ravulizumab-cwvz)

What is ULTOMIRIS?

ULTOMIRIS is a prescription medicine used to treat:

• adults and children 1 month of age and older with a disease called Paroxysmal Nocturnal Hemoglobinuria (PNH).
• adults and children 1 month of age and older with a disease called atypical Hemolytic Uremic Syndrome (aHUS). ULTOMIRIS is not used in treating people with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS).
• adults with a disease called generalized Myasthenia Gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.
• adults with PNH or aHUS when administered subcutaneously (under your skin).

It is not known if ULTOMIRIS is safe and effective in children younger than 1 month of age.

It is not known if ULTOMIRIS is safe and effective for the treatment of gMG in children.

Subcutaneous administration of ULTOMIRIS has not been evaluated and is not approved for use in children.

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about ULTOMIRIS?

ULTOMIRIS is a medicine that affects your immune system and can lower the ability of your immune system to fight infections.

• ULTOMIRIS increases your chance of getting serious and life-threatening meningococcal infections that may quickly become life-threatening and cause death if not recognized and treated early.

1. You must receive meningococcal vaccines at least 2 weeks before your first dose of ULTOMIRIS if you are not vaccinated.
2. If your healthcare provider decided that urgent treatment with ULTOMIRIS is needed, you should receive meningococcal vaccination as soon as possible.
3. If you have not been vaccinated and ULTOMIRIS therapy must be initiated immediately, you should also receive 2 weeks of antibiotics with your vaccinations.
4. If you had a meningococcal vaccine in the past, you might need additional vaccination. Your healthcare provider will decide if you need additional vaccination.
5. Meningococcal vaccines reduce but do not prevent all meningococcal infections. Call your healthcare provider or get emergency medical care right away if you get any of these signs and symptoms of a meningococcal infection: headache with nausea or vomiting, headache and fever, headache with a stiff neck or stiff back, fever, fever and a rash, confusion, muscle aches with flu-like symptoms and eyes sensitive to light.

Your healthcare provider will give you a Patient Safety Card about the risk of meningococcal infection. Carry it with you at all times during treatment and for 8 months after your last ULTOMIRIS dose. It is important to show this card to any healthcare provider or nurse to help them diagnose and treat you quickly.

ULTOMIRIS is only available through a program called the ULTOMIRIS REMS. Before you can receive ULTOMIRIS, your healthcare provider must: enroll in the ULTOMIRIS REMS program; counsel you about the risk of meningococcal infection; give you information and a Patient Safety Card about the symptoms and your risk of meningococcal infection (as discussed above); and make sure that you are vaccinated with a meningococcal vaccine, and if needed, get revaccinated with the meningococcal vaccine. Ask your healthcare provider if you are not sure if you need to be revaccinated.

ULTOMIRIS may also increase the risk of other types of serious infections. Make sure your child receives vaccinations against Streptococcus pneumoniae and Haemophilus influenzae type b (Hib) if treated with ULTOMIRIS. Call your healthcare provider right away if you have any new signs or symptoms of infection.

Who should not receive ULTOMIRIS?

Do not receive ULTOMIRIS if you have a meningococcal infection or have not been vaccinated against meningococcal infection unless your healthcare provider decides that urgent treatment with ULTOMIRIS is needed.

Before you receive ULTOMIRIS, tell your healthcare provider about all of your medical conditions, including if you: have an infection or fever, are pregnant or plan to become pregnant, and are breastfeeding or plan to breastfeed. It is not known if ULTOMIRIS will harm your unborn baby or if it passes into your breast milk. You should not breastfeed during treatment and for 8 months after your final dose of ULTOMIRIS.

Tell your healthcare provider about all the vaccines you receive and medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements which could affect your treatment.

If you have PNH and you stop receiving ULTOMIRIS, your healthcare provider will need to monitor you closely for at least 16 weeks after you stop ULTOMIRIS. Stopping ULTOMIRIS may cause breakdown of your red blood cells due to PNH. Symptoms or problems that can happen due to red blood cell breakdown include: drop in your red blood cell count, tiredness, blood in your urine, stomach-area (abdomen) pain, shortness of breath, blood clots, trouble swallowing, and erectile dysfunction (ED) in males.

If you have aHUS, your healthcare provider will need to monitor you closely for at least 12 months after stopping treatment for signs of worsening aHUS or problems related to a type of abnormal clotting and breakdown of your red blood cells called thrombotic microangiopathy (TMA). Symptoms or problems that can happen with TMA may include: confusion or loss of consciousness, seizures, chest pain (angina), difficulty breathing and blood clots or stroke.

ULTOMIRIS can cause serious side effects including allergic reactions to acrylic adhesive. Allergic reactions to the acrylic adhesive may happen with your subcutaneous ULTOMIRIS treatment. If you have an allergic reaction during the delivery of subcutaneous ULTOMIRIS, remove the on-body injector and get medical help right away. Your healthcare provider may treat you with medicines to help prevent or treat allergic reaction symptoms as needed.

What are the possible side effects of ULTOMIRIS?

ULTOMIRIS can cause serious side effects including infusion-related reactions. Symptoms of an infusion-related reaction with ULTOMIRIS may include lower back pain, tiredness, feeling faint, discomfort in your arms or legs, bad taste, or drowsiness. Stop treatment of ULTOMIRIS and tell your healthcare provider or nurse right away if you develop these symptoms, or any other symptoms during your ULTOMIRIS infusion that may mean you are having a serious infusion reaction, including: chest pain, trouble breathing or shortness of breath, swelling of your face, tongue, or throat, and feel faint or pass out

The most common side effects of ULTOMIRIS in people treated for PNH are upper respiratory tract infection and headache.

The most common side effects of ULTOMIRIS in people treated for aHUS are upper respiratory tract infection, diarrhea, nausea, vomiting, headache, high blood pressure and fever.

The most common side effects of ULTOMIRIS in people with gMG are diarrhea and upper respiratory tract infections.

The most common side effects of subcutaneous administration of ULTOMIRIS in adults treated for PNH and aHUS are local injection site reactions.

Tell your healthcare provider about any side effect that bothers you or that does not go away. These are not all the possible side effects of ULTOMIRIS. For more information, ask your healthcare provider or pharmacist. Call your healthcare provider right away if you miss an ULTOMIRIS infusion or for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Read the Instructions for Use that comes with subcutaneous ULTOMIRIS for instructions about the right way to prepare and give your subcutaneous ULTOMIRIS injections through an on-body injector.

Please see the accompanying full Prescribing Information and Medication Guide for ULTOMIRIS, including Boxed WARNING regarding serious and life-threatening meningococcal infections/sepsis. Please see the accompanying Instructions for Use for the ULTOMIRIS On Body Delivery System.

INDICATIONS & IMPORTANT SAFETY INFORMATION FOR SOLIRIS^® (eculizumab) [injection for intravenous use 300mg/30mL vial]

What is SOLIRIS?

SOLIRIS is a prescription medicine used to treat:

• patients with a disease called Paroxysmal Nocturnal Hemoglobinuria (PNH).
• adults and children with a disease called atypical Hemolytic Uremic Syndrome (aHUS). SOLIRIS is not for use in treating people with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS).
• adults with a disease called generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.
• adults with a disease called neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody positive.

It is not known if SOLIRIS is safe and effective in children with PNH, gMG, or NMOSD.

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about SOLIRIS?

SOLIRIS is a medicine that affects your immune system and can lower the ability of your immune system to fight infections.

• SOLIRIS increases your chance of getting serious and life-threatening meningococcal infections that may quickly become life-threatening and cause death if not recognized and treated early.
• You must receive meningococcal vaccines at least 2 weeks before your first dose of SOLIRIS if you are not vaccinated.
• If your doctor decided that urgent treatment with SOLIRIS is needed, you should receive meningococcal vaccination as soon as possible.
• If you have not been vaccinated and SOLIRIS therapy must be initiated immediately, you should also receive 2 weeks of antibiotics with your vaccinations.
• If you had a meningococcal vaccine in the past, you might need additional vaccination. Your doctor will decide if you need additional vaccination.
• Meningococcal vaccines reduce but do not prevent all meningococcal infections. Call your doctor or get emergency medical care right away if you get any of these signs and symptoms of a meningococcal infection: headache with nausea or vomiting, headache and fever, headache with a stiff neck or stiff back, fever, fever and a rash, confusion, muscle aches with flu-like symptoms, and eyes sensitive to light.

Your doctor will give you a Patient Safety Card about the risk of meningococcal infection. Carry it with you at all times during treatment and for 3 months after your last SOLIRIS dose. It is important to show this card to any doctor or nurse to help them diagnose and treat you quickly.

SOLIRIS is only available through a program called the SOLIRIS REMS. Before you can receive SOLIRIS, your doctor must enroll in the SOLIRIS REMS program; counsel you about the risk of meningococcal infection; give you information and a Patient Safety Card about the symptoms and your risk of meningococcal infection (as discussed above); and make sure that you are vaccinated with the meningococcal vaccine and, if needed, get revaccinated with the meningococcal vaccine. Ask your doctor if you are not sure if you need to be revaccinated.

SOLIRIS may also increase the risk of other types of serious infections. Make sure your child receives vaccinations against Streptococcus pneumoniae and Haemophilus influenzae type b (Hib) if treated with SOLIRIS. Certain people may be at risk of serious infections with gonorrhea. Certain fungal infections (Aspergillus) may occur if you take SOLIRIS and have a weak immune system or a low white blood cell count.

Who should not receive SOLIRIS?

Do not receive SOLIRIS if you have a meningococcal infection or have not been vaccinated against meningitis infection unless your doctor decides that urgent treatment with SOLIRIS is needed.

Before you receive SOLIRIS, tell your doctor about all of your medical conditions, including if you: have an infection or fever, are pregnant or plan to become pregnant, and are breastfeeding or plan to breastfeed. It is not known if SOLIRIS will harm your unborn baby or if it passes into your breast milk.

Tell your doctor about all the vaccines you receive and medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements which could affect your treatment. It is important that you have all recommended vaccinations before you start SOLIRIS, receive 2 weeks of antibiotics if you immediately start SOLIRIS, and stay up-to-date with all recommended vaccinations during treatment with SOLIRIS.

If you have PNH, your doctor will need to monitor you closely for at least 8 weeks after stopping SOLIRIS. Stopping treatment with SOLIRIS may cause breakdown of your red blood cells due to PNH. Symptoms or problems that can happen due to red blood cell breakdown include: drop in the number of your red blood cell count, drop in your platelet count, confusion, kidney problems, blood clots, difficulty breathing, and chest pain.

If you have aHUS, your doctor will need to monitor you closely during and for at least 12 weeks after stopping treatment for signs of worsening aHUS symptoms or problems related to abnormal clotting (thrombotic microangiopathy). Symptoms or problems that can happen with abnormal clotting may include: stroke, confusion, seizure, chest pain (angina), difficulty breathing, kidney problems, swelling in arms or legs, and a drop in your platelet count.

What are the possible side effects of SOLIRIS?

SOLIRIS can cause serious side effects including serious allergic reactions. Tell your doctor or nurse right away if you get any of these symptoms during your SOLIRIS infusion: chest pain; trouble breathing or shortness of breath; swelling of your face, tongue, or throat; and feel faint or pass out. If you have an allergic reaction to SOLIRIS, your doctor may need to infuse SOLIRIS more slowly, or stop SOLIRIS.

The most common side effects in people with PNH treated with SOLIRIS include: headache, pain or swelling of your nose or throat (nasopharyngitis), back pain, and nausea.

The most common side effects in people with aHUS treated with SOLIRIS include: headache, diarrhea, high blood pressure (hypertension), common cold (upper respiratory infection), stomach-area (abdominal) pain, vomiting, pain or swelling of your nose or throat (nasopharyngitis), low red blood cell count (anemia), cough, swelling of legs or feet (peripheral edema), nausea, urinary tract infections, and fever.

The most common side effects in people with gMG treated with SOLIRIS include: muscle and joint (musculoskeletal) pain.

The most common side effects in people with NMOSD treated with SOLIRIS include: common cold (upper respiratory infection); pain or swelling of your nose or throat (nasopharyngitis); diarrhea; back pain; dizziness; flu-like symptoms (influenza), including fever, headache, tiredness, cough, sore throat, and body aches; joint pain (arthralgia); throat irritation (pharyngitis); and bruising (contusion).

Tell your doctor about any side effect that bothers you or that does not go away. These are not all the possible side effects of SOLIRIS. For more information, ask your doctor or pharmacist. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch, or call 1-800-FDA-1088.

Please see the full Prescribing Information and Medication Guide for SOLIRIS, including Boxed WARNING regarding serious and life-threatening meningococcal infections.

Notes

ULTOMIRIS

ULTOMIRIS (ravulizumab-cwvz), the first and only long-acting C5 complement inhibitor, offers immediate, complete and sustained complement inhibition. The medication works by inhibiting the C5 protein in the terminal complement cascade, a part of the body’s immune system. When activated in an uncontrolled manner, the complement cascade over-responds, leading the body to attack its own healthy cells.ULTOMIRIS is administered intravenously every eight weeks in adult patients, following a loading dose.

ULTOMIRIS is approved in the US, EU and Japan for the treatment of certain adults with gMG.

ULTOMIRIS is also approved in the US, EU and Japan for the treatment of certain adults with PNH and for certain children with PNH in the US and EU.

Additionally, ULTOMIRIS is approved in the US, EU and Japan for certain adults and children with aHUS to inhibit complement-mediated thrombotic microangiopathy.

As part of a broad development program, ULTOMIRIS is being assessed for the treatment of additional hematology and neurology indications.

SOLIRIS

SOLIRIS (eculizumab) is a first-in-class C5 complement inhibitor. The medication works by inhibiting the C5 protein in the terminal complement cascade, a part of the body’s immune system. When activated in an uncontrolled manner, the terminal complement cascade over-responds, leading the body to attack its own healthy cells. SOLIRIS is administered intravenously every two weeks, following an introductory dosing period.

SOLIRIS is approved in the US, EU and Japan for the treatment of PNH, aHUS, certain adults with gMG and certain adults with NMOSD.

SOLIRIS is not indicated for the treatment of patients with STEC-HUS.

Alexion

Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. As a leader in rare diseases for more than 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology and ophthalmology. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries. For more information, please visit www.alexion.com.

AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca-us.com and follow us on Twitter @AstraZenecaUS.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230227005822/en/

Media Inquiries

Alexion Media Mailbox: [email protected]

KEYWORDS: United States North America Delaware

INDUSTRY KEYWORDS: Research Neurology FDA Clinical Trials Other Health Biotechnology Pharmaceutical Health Science Other Science

MEDIA:

Posted on March 2, 2023 5:26 pm

Ecovyst Announces Secondary Offering of 11,490,444 Shares of Common Stock by Selling Stockholders and Repurchase of Common Stock

Ecovyst Announces Secondary Offering of 11,490,444 Shares of Common Stock by Selling Stockholders and Repurchase of Common Stock

MALVERN, PA.–(BUSINESS WIRE)–
Ecovyst Inc. (NYSE: ECVT) (the “Company”) today announced that funds affiliated with CCMP Capital Advisors, LP (the “Selling Stockholders”) intend to offer for sale their remaining interest in the Company, 11,490,444 shares of the Company’s common stock, pursuant to the Company’s shelf registration statement filed with the Securities and Exchange Commission (the “Offering”).

The Selling Stockholders will receive all of the net proceeds from the Offering. No shares are being sold by the Company.

Subject to the completion of the Offering, the Company intends to repurchase from the underwriter 3,000,000 shares of the common stock being sold in the Offering at a price per share equal to the price per share paid by the underwriter to the Selling Stockholders in the Offering. The Company intends to fund the share repurchase with cash on hand and cash from operations. The closing of the share repurchase is conditioned on, and expected to occur simultaneously with, the closing of the Offering. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed.

Jefferies is serving as the underwriter for the Offering.

An automatic shelf registration statement (including a prospectus) relating to the Offering was filed with the Securities and Exchange Commission (“SEC”) on April 26, 2021 and became effective upon filing. Before you invest, you should read the prospectus included in that registration statement and the documents incorporated by reference in that registration statement as well as the prospectus supplement related to the Offering. You may obtain these documents for free by visiting EDGAR on the SEC website at www.sec.gov. When available, copies of the prospectus supplement and accompanying prospectus related to the Offering may also be obtained from Jefferies LLC, at Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, by telephone at 877-821-7388, or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. Any offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time prior to notice of its acceptance given after the effective date.

About Ecovyst

Ecovyst Inc. and subsidiaries is a leading integrated and innovative global provider of specialty catalysts and services. We support customers globally through our strategically located network of manufacturing facilities. We believe that our products, which are predominantly inorganic, and services contribute to improving the sustainability of the environment.

We have two uniquely positioned specialty businesses: Ecoservices provides sulfuric acid recycling to the North American refining industry for the production of alkylate and provides on-purpose virgin sulfuric acid for water treatment, mining, and industrial applications; and Catalyst Technologies provides finished silica catalysts and catalyst supports necessary to produce high strength and high stiffness plastics and, through its Zeolyst joint venture, supplies zeolites used for catalysts that help produce renewable fuels, remove nitrogen oxides from diesel engine emissions as well as sulfur from fuels during the refining process.

Note on Forward-Looking Statements

This press release includes statements that express our opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results and therefore are, or may be deemed to be, “forward-looking statements.” These forward-looking statements can generally be identified by the use of forward-looking terminology, including the terms “believes,” “expects,” “may,” “will,” “should,” “seeks,” “projects,” “approximately,” “intends,” “plans,” “estimates” or “anticipates,” or, in each case, their negatives or other variations or comparable terminology. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future, including risks and uncertainties relating to the consummation of the proposed Offering by the Selling Stockholders, the repurchase of common stock, and the risks identified, or incorporated by reference, in the prospectus supplement or accompanying prospectus.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230302005757/en/

Investor Contact:

Gene Shiels

(484) 671-1225

[email protected]

KEYWORDS: Pennsylvania United States North America

INDUSTRY KEYWORDS: Manufacturing Other Manufacturing Environment Sustainability Chemicals/Plastics

MEDIA:

Posted on March 2, 2023 5:25 pm

Cybin and The Chopra Foundation to Participate in Featured Session at Upcoming 2023 South by Southwest® Conference

Cybin and The Chopra Foundation to Participate in Featured Session at Upcoming 2023 South by Southwest^® Conference

– Cybin CEO, Doug Drysdale and Wellness Icon Deepak Chopra to be featured on panel titled Open Minds: Innovations in Consciousness, Psychedelics & Mental Health –

TORONTO–(BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics^® and The Chopra Foundation, a not-for-profit organization dedicated to improving health and well-being founded by Dr. Deepak Chopra, are pleased to announce that Dr. Chopra and Chief Executive Officer of Cybin, Doug Drysdale will be featured on a panel at the upcoming South by Southwest^® (SXSW^®) Conference taking place in Austin, TX March 10 – 19, 2023. The panel titled, Open Minds: Innovations in Consciousness, Psychedelics & Mental Health, will be held on Sunday, March 12, 2023 at 11:30am CT at the Austin Convention Center. For more information on SXSW and the featured panel, please click here.

Psychedelic-based therapies continue to influence the evolving landscape of mental health. As humanity begins to understand the complexity of consciousness and its impact on mental health, these worlds will become increasingly intertwined. In the featured SXSW panel session, Dr. Chopra, Mr. Drysdale and guests, including Cristie Strongman MA, Ed.M., Psychotherapist at the Multidisciplinary Association for Psychedelic Studies (MAPS) and Gabriella Wright,actress, activist, and co-founder of the Never Alone Alliance, will discuss and explore the connection between consciousness, mental health, and psychedelic therapeutics and the need for humanity to focus on the internal work required to heal.

These leading industry experts are also featured in the upcoming six-part miniseries Open Minds: Exploring Psychedelic Medicine that addresses the topics of consciousness, the experience of using psychedelic treatments, the current research landscape and what the future of mental healthcare may look like. The miniseries also features researcher Dennis McKenna, who has conducted interdisciplinary research on the ethnopharmacology of Amazonian traditional medicines for over 40 years, Bryan Johnson, Founder and CEO of Kernel, Keith Ferrazzi, Founder and Chairman of Ferrazzi Greenlight, and Adam Strauss, comedian and psychedelic advocate.

Open Minds is produced by the progressive streaming network ALTRD.TV. ALTRD is home to feature films, documentaries, and original TV series focused on disruptive markets and the modern counterculture. Open Minds will be released on April 19, 2023 on all smart devices everywhere and at www.altrd.tv. For more information on Open Minds please visit https://www.thefutureofpsychedelictherapy.com/.

About ALTRD.TV

ALTRD TV is the streaming network for progressive culture featuring content from top creators in web3, transformative wellness, NFTs and animation, and more. Audiences can watch thousands of free and unlimited features, docs, and series on smart devices and TVs in 65M+ homes, on networks including AppleTV/ios, Android, Samsung+, Plex, Roku, LG, and Playstation.

ALTRD.TV Contact:

Joshua Otten

Co-Founder and CEO

[email protected]

About Cybin

Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. The Company is focused on progressing Psychedelics to Therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.

About The Chopra Foundation and Never Alone Alliance

The Chopra Foundation is a 501 (c) (3) organization (#36-4793898) dedicated to improving health and well-being, cultivating spiritual knowledge, expanding consciousness, and promoting world peace to all members of the human family. The Foundation’s Never Alone movement will be providing the world with the tools to proactively pursue their path to joy and freedom from suffering.

Media Inquiries:

Kristen Marion

[email protected]

623-308-2638

View source version on businesswire.com: https://www.businesswire.com/news/home/20230302005872/en/

Cybin Contacts:

Leah Gibson

Vice President, Investor Relations & Strategic Communications

Cybin Inc.

[email protected]

Gabriel Fahel

Chief Legal Officer

Cybin Inc.

1-866-292-4601

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: Alternative Medicine Health Clinical Trials Research Science Pharmaceutical Biotechnology

MEDIA:

Posted on March 2, 2023 5:24 pm

AppFolio Announces Leadership Transition

Shane Trigg unanimously elected as AppFolio’s President and Chief Executive Officer

Company reaffirms 2023 outlook

SANTA BARBARA, Calif., March 02, 2023 (GLOBE NEWSWIRE) — AppFolio, Inc. (NASDAQ:APPF), a leading provider of cloud business management solutions for the real estate industry, announced that the Board of Directors has unanimously elected Shane Trigg as President and Chief Executive Officer, effective immediately. Trigg previously served as AppFolio’s President and General Manager, Real Estate. Jason Randall, who has served as President and Chief Executive Officer since 2017, will be a transition advisor to the company until March 31, 2023.

A seasoned SaaS executive with more than 25 years of experience driving growth at successful software companies such as Salesforce and Intuit, Trigg joined AppFolio in April 2020 as the General Manager of Real Estate, leading strategy and operations for AppFolio Property Manager product and service offerings. He was named President of Real Estate in February 2023. Since Trigg’s arrival, he has helped lead AppFolio’s rapid progress toward its goal to digitally transform the real estate industry through a differentiated product vision that supports upmarket expansion and a go-to-market strategy that inspires customers to choose and grow with AppFolio, while building and leading high-performing teams.

Andreas von Blottnitz, Chairman of the AppFolio Board of Directors, stated, “On behalf of the Board, we thank Jason for his meaningful contributions – overseeing AppFolio’s success in creating value for customers and shareholders for nearly 15 years in a leadership capacity, including the last five as President and CEO where Jason oversaw substantial growth. We are grateful for his continued service to AppFolio during this transition as we build for this next exciting chapter.”

Trigg’s ascension is part of a multi-year succession plan, during which time the Board had an opportunity to recognize Trigg’s contributions to the company, and Randall and Trigg worked together to organize for growth and ensure values were aligned.

“I am very proud of our accomplishments during my almost 15 years at AppFolio,” said Randall. “My proudest moments have been watching our team and company thrive and grow. The past three years working with Shane have been especially rewarding and I am extremely excited for him and the future at AppFolio.”

“Real Estate businesses depend upon the right technology partner now more than ever to achieve their goals around growth, efficiency, and delivering exceptional experiences to their customers,” said Trigg. “I am honored to lead AppFolio through our next growth phase — rooted in our values, inspired by our customers, and fueled by our world-class innovation and people. We have an incredible opportunity to leverage our core platform in property management and grow our return on investment.”

Today AppFolio also announced changes to its Board of Directors. Trigg will assume the board seat previously held by Randall. Additionally, AppFolio Co-Founder and former Chief Strategy Officer Klaus Schauser will transition from a board director to a board observer. Filling his vacant seat will be Olivia Nottebohm, former Chief Operating Officer of Dropbox and a 20-year veteran of online software businesses. These changes are effective immediately.

Lastly, AppFolio has reaffirmed its full year 2023 guidance previously disclosed in connection with the announcement of AppFolio’s fourth quarter and 2022 full year financial results on January 26, 2023.

About AppFolio, Inc.

AppFolio, Inc. is a leading provider of cloud business management solutions for the real estate industry. Our solutions enable our customers to digitally transform their businesses, address critical business operations and deliver a better customer experience. For more information about AppFolio, visit www.appfolioinc.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which statements are subject to considerable risks and uncertainties. Forward-looking statements include all statements that are not statements of historical fact contained in this press release, and can be identified by words such as “anticipates,” “believes,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts, “projects,” “seeks,” “should,” “will,” “would” or similar expressions and the negatives of those expressions. In particular, forward-looking statements contained in this press release relate to future operating results and financial position, including the Company’s fiscal year 2023 financial outlook, anticipated future expenses and investments, the Company’s business opportunities, and the impact of the Company’s strategic actions and initiatives.

Forward-looking statements represent AppFolio’s current beliefs and assumptions based on information currently available. Forward-looking statements involve numerous known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Some of the risks and uncertainties that may cause the Company’s actual results to materially differ from those expressed or implied by these forward-looking statements are described in the section entitled “Risk Factors” in AppFolio’s Annual Report on Form 10-K for the year ended December 31, 2022, which was filed with the SEC on February 9, 2023, as well as in the Company’s other filings with the SEC. You should read this press release with the understanding that the Company’s actual future results may be materially different from the results expressed or implied by these forward looking statements.

Except as required by applicable law or the rules of the NASDAQ Global Market, AppFolio assumes no obligation to update any forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/636d7c60-bb9b-4adc-86a4-eb01629f0c4c

 

For more information, please contact:
Stephanie Mitchell
[email protected]

Lori Barker
[email protected]

Posted on March 2, 2023 5:23 pm

USD Partners LP Announces Annual Report on Form 10-K for the Year Ended December 31, 2022, and 2022 Schedule K-1 Availability

USD Partners LP Announces Annual Report on Form 10-K for the Year Ended December 31, 2022, and 2022 Schedule K-1 Availability

HOUSTON–(BUSINESS WIRE)–
USD Partners LP (NYSE: USDP) (the “Partnership”) today announced that the Partnership filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2022, with the U.S. Securities and Exchange Commission (“SEC”). The Partnership’s Annual Report on Form 10-K is available through its website at www.usdpartners.com by selecting the “SEC Filings” sub-tab under the “Investors” tab, as well as on the SEC’s website at www.sec.gov. Interested investors may obtain a hard copy of the Annual Report on Form 10-K, including the Partnership’s financial statements, free of charge by writing to Investor Relations, USD Partners LP, 811 Main Street, Suite 2800, Houston, Texas 77002 or emailing [email protected].

Additionally, the Partnership’s 2022 tax package, which includes the Schedule K-1 (Form 1065), will be made available by March 10, 2023 and may be accessed on the Partnership’s website at www.usdpartners.com by selecting the “K-1 Tax Information” sub-tab under the “Investors” tab. Printed copies of the tax package will be mailed by the week of March 13, 2023. For additional information or assistance, unitholders may contact the toll free USD Partners LP Tax Support Line at 1-844-275-9876.

About USD Partners LP

USD Partners LP is a fee-based, growth-oriented master limited partnership formed in 2014 by US Development Group, LLC (“USD”) to acquire, develop and operate midstream infrastructure and complementary logistics solutions for crude oil, biofuels and other energy-related products. The Partnership generates substantially all of its operating cash flows from multi-year, take-or-pay contracts with primarily investment grade customers, including major integrated oil companies and refiners. The Partnership’s principal assets include a network of crude oil terminals that facilitate the transportation of heavy crude oil from Western Canada to key demand centers across North America. The Partnership’s operations include railcar loading and unloading, storage and blending in on-site tanks, inbound and outbound pipeline connectivity, truck transloading, as well as other related logistics services. In addition, the Partnership provides customers with leased railcars and fleet services to facilitate the transportation of liquid hydrocarbons and biofuels by rail.

USD, which owns the general partner of USD Partners LP, is engaged in designing, developing, owning, and managing large-scale multi-modal logistics centers and energy-related infrastructure across North America. USD’s solutions create flexible market access for customers in significant growth areas and key demand centers, including Western Canada, the U.S. Gulf Coast and Mexico. Among other projects, USD is currently pursuing the development of a premier energy logistics terminal on the Houston Ship Channel with capacity for substantial tank storage, multiple docks (including barge and deepwater), inbound and outbound pipeline connectivity, as well as a rail terminal with unit train capabilities. For additional information, please visit texasdeepwater.com. Information on websites referenced in this release is not part of this release.

Category: Earnings

View source version on businesswire.com: https://www.businesswire.com/news/home/20230302005718/en/

Adam Altsuler

Executive Vice President, Chief Financial Officer

(281) 291-3995

[email protected]

Jennifer Waller

Director, Financial Reporting & Investor Relations

(281) 991-8383

[email protected]

KEYWORDS: Texas United States North America

INDUSTRY KEYWORDS: Oil/Gas Rail Energy Logistics/Supply Chain Management Transport

MEDIA:

Logo